NuvOx Therapeutics

NuvOx Therapeutics is advancing NanO₂, a novel oxygen therapeutic, through mid-stage clinical trials targeting conditions where hypoxia is a key driver of pathology. The company has active Phase IIb trials in glioblastoma and stroke, with a Phase Ib trial in respiratory distress planned, supported by significant non-dilutive funding from U.S. and U.K. government agencies. Its platform has demonstrated therapeutic effects in over 30 animal studies across seven indications, positioning it to address high-unmet-need areas in oncology, neurology, and critical care. NuvOx remains a private, pre-revenue company leveraging grant and partnership capital to de-risk its clinical programs.

A first-in-class oxygen therapeutic platform designed to reverse tissue hypoxia by improving oxygen delivery from lungs to blood and from blood to tissue. It has shown activity as both a radiosensitizer and a neuroprotectant in preclinical models.

The field of oxygen therapeutics and hypoxia-targeting drugs is niche but includes approaches like hyperbaric oxygen, hemoglobin-based oxygen carriers (largely discontinued due to safety issues), and HIF (Hypoxia-Inducible Factor) inhibitors. NuvOx's NanO₂ appears distinct as a potential oxygen-delivering therapeutic agent. In glioblastoma, it would compete as a radiosensitizer against other investigational agents and device-based approaches. In stroke, it faces competition from other neuroprotectants and next-generation thrombectomy technologies.